What Joe Rogan's TRT Protocol Would Cost Outside a Celebrity Context

At a glance
- Celebrity: Joe Rogan
- Drug family: Testosterone replacement therapy (TRT)
- Status: Confirmed by Rogan himself across multiple podcast episodes spanning 2012 to present
- Associated compounds discussed publicly: Testosterone cypionate, HGH (referenced), BPC-157, NAD+, ipamorelin (discussed in guest segments)
- Estimated annual cost for a non-celebrity patient: $1,200 to $6,000+, depending on protocol scope and insurance
- Insurance coverage outlook: Testosterone cypionate commonly covered with documented hypogonadism; peptides and HGH rarely covered for optimization purposes
What Joe Rogan Has Actually Said
Joe Rogan's disclosure of TRT use is not ambiguous. He has confirmed it on The Joe Rogan Experience in multiple episodes dating back to at least 2012, stating plainly that he began testosterone replacement in his early 40s after bloodwork showed declining levels. In a widely cited 2018 episode with guest Dr. Mark Gordon, Rogan described his protocol as including testosterone cypionate injections and referenced periodic bloodwork monitoring (JRE #1056, YouTube).
Rogan has also publicly discussed using BPC-157 for injury recovery, mentioning it across several episodes including conversations with Ben Greenfield and Dr. Andrew Huberman. He has referenced NAD+ infusions in the context of recovery and energy. During episodes featuring longevity physicians, he has discussed ipamorelin and growth hormone secretagogues, though his own confirmed use of these specific peptides is less clearly delineated than his testosterone use.
The distinction matters. Testosterone replacement: confirmed, first-person, repeated. HGH use: Rogan has discussed growth hormone in favorable terms but has been less explicit about sustained personal use. BPC-157: confirmed use for specific injury contexts. NAD+: confirmed use. Ipamorelin: discussed favorably with guests, personal use not explicitly confirmed in the same direct manner.
The Clinical Basis for TRT
Testosterone replacement therapy treats hypogonadism, a condition where the testes produce insufficient testosterone. Age-related decline begins around age 30 at roughly 1% to 2% per year, and by their mid-40s, a meaningful percentage of men fall below the 300 ng/dL threshold that most endocrinologists use as a clinical floor (Endocrine Society Clinical Practice Guidelines, 2018).
Symptoms of low testosterone include fatigue, reduced muscle mass, increased body fat, diminished libido, mood changes, and decreased bone mineral density. The standard treatment for confirmed hypogonadism is exogenous testosterone, most commonly testosterone cypionate administered via intramuscular injection every 1 to 2 weeks, or testosterone enanthate on a similar schedule.
The FDA has approved testosterone products specifically for men with documented low testosterone caused by medical conditions (primary or secondary hypogonadism confirmed by lab testing). The agency issued a 2015 safety communication cautioning against use for age-related decline alone, a nuance that directly affects insurance coverage decisions.
Breaking Down the Cost: Testosterone Alone
For a patient with confirmed hypogonadism and a willing prescriber, generic testosterone cypionate is one of the more affordable prescription medications in the hormone space.
With insurance (diagnosed hypogonadism):
- Testosterone cypionate 200 mg/mL, 10 mL vial: $0 to $30 copay at most commercial pharmacies
- Syringes and needles: typically $10 to $25 per quarter
- Lab monitoring (total testosterone, free testosterone, hematocrit, PSA, lipid panel): $0 to $50 per draw with insurance, typically 2 to 4 times per year
- Prescriber visits: $25 to $75 copay, 2 to 4 per year
Annual estimate with insurance: $300 to $900
Without insurance (cash pay):
- Testosterone cypionate 200 mg/mL, 10 mL vial: $40 to $100 at retail pharmacy, $30 to $60 via GoodRx-type discount
- Lab panels: $100 to $300 per draw at direct-pay labs
- Telehealth TRT clinic visits: $100 to $200 per month (many bundle labs and medication)
Annual estimate without insurance, self-managed: $800 to $1,800 Annual estimate via TRT telehealth clinic: $1,200 to $2,400
The branded options (Androgel topical, Natesto nasal, Jatenzo oral) cost dramatically more. Androgel runs $500 to $700 per month without insurance. For injectable cypionate, generics dominate and the economics favor the patient.
Adding the Extras Rogan Has Discussed
This is where the cost profile shifts. The peptides and adjuncts Rogan has publicly associated with his wellness routine sit largely outside insurance formularies.
BPC-157 (Body Protection Compound-157): Rogan has confirmed using BPC-157 for injury recovery. BPC-157 is a synthetic peptide derived from a gastric protein, studied primarily in animal models for tissue repair. It is not FDA-approved. Patients access it through compounding pharmacies or research peptide suppliers. Cost: $50 to $150 per vial (5 mg), with a typical 4-week protocol running $100 to $300 depending on dosing. Insurance coverage: none.
NAD+ (Nicotinamide Adenine Dinucleotide) Infusions: Rogan has discussed receiving NAD+ IV infusions. NAD+ is a coenzyme involved in cellular energy metabolism, and IV administration has been promoted in longevity circles despite limited clinical trial data in healthy adults. A single IV session runs $250 to $1,000 depending on the clinic and dosage. A monthly protocol adds $3,000 to $12,000 per year. Insurance coverage: none for optimization purposes.
Ipamorelin / Growth Hormone Secretagogues: Discussed on Rogan's podcast in the context of guest conversations about growth hormone optimization. Ipamorelin stimulates pulsatile GH release. It is not FDA-approved. Compounding pharmacy cost: $100 to $300 per month. Insurance coverage: none.
HGH (Somatropin): Rogan has referenced growth hormone use in general terms. Pharmaceutical-grade HGH (Genotropin, Norditropin, Humatrope) is FDA-approved only for specific conditions including adult growth hormone deficiency. Cash-pay cost for optimization doses (1 to 2 IU/day): $500 to $1,500 per month. Insurance coverage for age-related optimization: almost universally denied.
The Real Access Gap
The HealthRX Medical Team's assessment: testosterone cypionate itself is accessible and affordable. The barrier most men encounter is not the drug price but the diagnostic gatekeeping. Many primary care physicians remain reluctant to prescribe TRT for borderline levels (300 to 400 ng/dL), even when patients present with clear symptoms. This pushes patients toward cash-pay telehealth clinics that charge monthly subscription fees.
The peptide and HGH layer operates in a different economy entirely. These compounds sit in a regulatory gray zone. The FDA's 2023 enforcement actions against compounding pharmacies selling certain peptides (including some related to GH secretagogues) have narrowed legal access channels. Patients pursuing a Rogan-adjacent protocol must manage compounding pharmacy relationships, prescriber willingness, and entirely out-of-pocket costs.
A realistic annual budget for a non-celebrity replicating the full scope of what Rogan has publicly described:
| Component | Low Estimate | High Estimate | |---|---|---| | Testosterone cypionate + supplies | $300 | $1,800 | | Lab monitoring | $200 | $1,200 | | Prescriber visits | $100 | $800 | | BPC-157 (periodic use) | $200 | $600 | | NAD+ (monthly IV) | $3,000 | $12,000 | | Ipamorelin (if used) | $1,200 | $3,600 | | Total | $5,000 | $20,000 |
Strip away everything except the testosterone, labs, and doctor visits, and the cost drops to $600 to $3,800 per year. The gap between those numbers tells you exactly where the celebrity-context premium lives.
What the HealthRX Medical Team Recommends Knowing
Rogan's public openness about TRT has done something unusual: it has given millions of men a framework for discussing hormone health with less stigma. That is genuinely useful. The risk is that listeners hear the full protocol (testosterone plus peptides plus NAD+ plus HGH) and perceive it as a single package rather than a tiered decision tree.
The HealthRX Medical Team's position: if bloodwork confirms low testosterone with symptoms, TRT via testosterone cypionate is a well-studied, evidence-based intervention with decades of safety data when properly monitored. Hematocrit monitoring is essential, as testosterone increases red blood cell production and can raise cardiovascular risk if polycythemia develops.
The peptide and HGH layer carries a fundamentally different evidence profile. BPC-157 has promising animal data but no completed Phase III human trials. NAD+ IV infusions lack rigorous RCT evidence for the longevity claims made by clinics charging premium prices. Ipamorelin's safety profile in long-term human use is not established.
Patients should ask their prescriber three questions before starting any protocol: What is the evidence level for this specific compound? What monitoring do I need? What is my realistic annual cost, including labs?
Rogan can afford concierge medicine. Most patients cannot. The good news: the single highest-impact component of his protocol, testosterone cypionate, is also the cheapest and best-studied.
Frequently asked questions
›
›
›
›
›
References
- Endocrine Society Clinical Practice Guidelines for Testosterone Therapy (2018)
- FDA Safety Communication on Testosterone Products (2015)
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
- BPC-157: Stable Gastric Pentadecapeptide and Wound Healing (2018)
- NAD+ Metabolism and Its Roles in Cellular Processes (2021)
- Growth Hormone Deficiency in Adults: AACE Guidelines
- Testosterone Treatment and Cardiovascular Events: TRAVERSE Trial
- Testosterone-Induced Polycythemia: Diagnosis and Management
- FDA Enforcement on Compounding Pharmacies (2023)